Literature DB >> 28500685

Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid.

Katja Bieber1, Anna Lara Ernst1, Stefan Tukaj2, Maike M Holtsche3, Enno Schmidt1,3, Detlef Zillikens1,3, Ralf J Ludwig1,3, Michael Kasperkiewicz3.   

Abstract

Experimental models of bullous pemphigoid (BP), the most frequent subepidermal autoimmune bullous disease, revealed that the immune response leading to blister formation represents an incompletely understood complex process involving different inflammatory cells. In contrast to previous reports commonly focusing on limited molecular and cellular phenotypes of the disease, the aim of this study was to investigate a broad spectrum of markers of cellular immune activation in patients with BP. We found that serum levels of soluble CD4, myeloperoxidase, S100A12, eosinophil cationic protein and soluble P-selectin were significantly elevated in patients with active BP compared with normal controls. Mast cell tryptase and neopterin serum levels significantly decreased at the time of clinical remission of the patients. Additionally, serum concentrations of soluble IL-2 receptor, mast cell tryptase and soluble P-selectin were significantly associated with levels of circulating anti-BP180 autoantibodies. Our findings confirm and extend previous reports suggesting some concomitant involvement of a panel of molecules representative for a wide spectrum of cellular players (T cells, mast cells, neutrophils, eosinophils, macrophages and platelets) orchestrating the inflammatory reaction in BP. These data may favour the employment of broad-spectrum or combined immunosuppressants, potentially together with an anticoagulant treatment, over cell- or molecule-specific targeted therapy in patients with this disorder.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autoantibody; inflammation; pemphigoid

Mesh:

Substances:

Year:  2017        PMID: 28500685     DOI: 10.1111/exd.13382

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  14 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 2.  Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases.

Authors:  Pavel Kolkhir; Daniel Elieh-Ali-Komi; Martin Metz; Frank Siebenhaar; Marcus Maurer
Journal:  Nat Rev Immunol       Date:  2021-10-05       Impact factor: 53.106

Review 3.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

Review 4.  Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Mansour Seaf; Giancarlo Marone; Francesca Levi-Schaffer; Gianni Marone
Journal:  Front Med (Lausanne)       Date:  2017-07-24

Review 5.  Current Clinical Trials in Pemphigus and Pemphigoid.

Authors:  Kentaro Izumi; Katja Bieber; Ralf J Ludwig
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

Review 6.  New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update.

Authors:  Giovanni Genovese; Giovanni Di Zenzo; Emanuele Cozzani; Emilio Berti; Massimo Cugno; Angelo Valerio Marzano
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

Review 7.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

Review 8.  The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury.

Authors:  Hui Fang; Yang Zhang; Ning Li; Gang Wang; Zhi Liu
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

Review 9.  The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease.

Authors:  Kyle T Amber; Manuel Valdebran; Khalaf Kridin; Sergei A Grando
Journal:  Front Med (Lausanne)       Date:  2018-07-10

Review 10.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.